Search results for " COLORECTAL CANCER"

showing 10 items of 120 documents

Nobiletin and xanthohumol sensitize colorectal cancer stem cells to standard chemotherapy

2021

Simple Summary Colorectal cancer stem cells (CR-CSCs) play a pivotal role in the therapy resistance and relapse of CRC patients. Herein we demonstrate that new treatment approaches comprising polymethoxyflavones and prenylflavonoids extracted from Citrus sinensis and Humulus lupulus, respectively, hamper the viability of CR-CSCs as well as synergizing with 5-fluorouracil and oxaliplatin (FOX)-based chemotherapy. Extract fractions containing Nobiletin and Xanthohumol, in combination with chemotherapy, decreased stemness properties of CR-CSCs and restrained the outgrowth of chemoresistant metastatic CR-CSCs. These data pinpoint Nobiletin and Xanthohumol as efficacious anti-cancer compounds in…

0301 basic medicinecancer stem cellCancer ResearchAnti-cancer therapyColorectal cancermedicine.medical_treatmentArticleNobiletin03 medical and health sciences0302 clinical medicineCancer stem cellSettore MED/04 - PATOLOGIA GENERALEMedicineflavonoidClonogenic assayRC254-282FlavonoidsChemotherapybusiness.industryCancer stem cellsWnt signaling pathwayXanthohumolNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell cyclemedicine.diseaseColorectal cancerOxaliplatin030104 developmental biologyOncologyflavonoids; nobiletin; xanthohumol; anti-cancer therapy; cancer stem cells; colorectal cancer; natural biofunctional molecules030220 oncology & carcinogenesisCancer researchNatural biofunctional moleculesStem cellbusinessanti-cancer therapy; cancer stem cells; colorectal cancer; flavonoids; natural biofunctional molecules; nobiletin; xanthohumolmedicine.drug
researchProduct

Non-coding RNAs Functioning in Colorectal Cancer Stem Cells

2016

In recent years, the hypothesis of the presence of tumor-initiating cancer stem cells (CSCs) has received a considerable support. This model suggested the existence of CSCs which, thanks to their self-renewal properties, are able to drive the expansion and the maintenance of malignant cell populations with invasive and metastatic potential in cancer. Increasing evidence showed the ability of such cells to acquire self-renewal, multipotency, angiogenic potential, immune evasion, symmetrical and asymmetrical divisions which, along with the presence of several DNA repair mechanisms, further enhance their oncogenic potential making them highly resistant to common anticancer treatments. The main…

0301 basic medicinemedicine.disease_cause03 medical and health sciences0302 clinical medicineCancer stem cellEpithelialmesenchymal transitionmicroRNAmedicineEpithelial–mesenchymal transitionSonic hedgehogNon-coding RNACancer stem cells; Colorectal cancer; Differentiation; Epithelialmesenchymal transition; MicroRNAs; Non-coding RNAs; Self-renewal; Signaling pathways; Stemness; Tumorigenicity; Medicine (all); Biochemistry Genetics and Molecular Biology (all)TumorigenicityStemneBiochemistry Genetics and Molecular Biology (all)biologySignaling pathwayCancer stem cellMedicine (all)Wnt signaling pathwayCancerMicroRNAmedicine.diseaseColorectal cancerCell biology030104 developmental biologyDifferentiation030220 oncology & carcinogenesisbiology.proteinSelf-renewalStem cellCarcinogenesis
researchProduct

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-pe…

2018

// Pierpaolo Correale 1 , Cirino Botta 2 , Nicoletta Staropoli 3 , Valerio Nardone 4 , Pierpaolo Pastina 4 , Cristina Ulivieri 5 , Claudia Gandolfo 6 , Tatiana Cosima Baldari 5 , Stefano Lazzi 7 , Domenico Ciliberto 3 , Rocco Giannicola 1 , Antonella Fioravanti 8 , Antonio Giordano 9 , Silvia Zappavigna 10 , Michele Caraglia 9, 10 , Pierfrancesco Tassone 2, 3, 10 , Luigi Pirtoli 4 , Maria Grazia Cusi 6 and Pierosandro Tagliaferri 3 1 Unit of Medical Oncology, Grand Metropolitan Hospital Bianchi Melacrino Morelli, Reggio-Calabria, Italy 2 Medical Oncology Unit, AUO Mater Domini, Magna Graecia University, Catanzaro, Italy 3 Department of Experimental and Clinical Medicine, Magna Graecia Unive…

0301 basic medicinemedicine.medical_specialtyColorectal cancerThymidylate synthaseK-ra03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalCancer vaccineMedicineIn patientK-rasAntitumor activitybiologybusiness.industryBio-markerUniversity hospitalmedicine.diseasePredictive valueColorectal cancerClinical trial030104 developmental biologyBio-markers; Cancer vaccine; Colorectal cancer; K-ras; Thymidylate synthase; OncologyOncology030220 oncology & carcinogenesisbiology.proteinThymidylate synthaseBio-markersbusinessResearch Paper
researchProduct

The Hippo Show Must Go On: YAP Activation as a Therapeutic Strategy in Colorectal Cancer

2020

The role of Hippo pathway in colorectal cancer (CRC) initiation and progression has been controversial. In this issue of Cell Stem Cell, Cheung et al. (2020) shed new light on a distinct function of the transcriptional co-activator YAP as a tumor suppressor and Wnt pathway inhibitor in CRC.

0303 health sciencesHippo signaling pathwayColorectal cancerCellWnt signaling pathwayCell BiologyBiologymedicine.diseasedigestive system diseaseslaw.invention03 medical and health sciences0302 clinical medicinemedicine.anatomical_structurelawGeneticsmedicineCancer researchMolecular MedicineSuppressorYAP colorectal cancer Hippo pathway Wnt pathwayStem cellTranscription factor030217 neurology & neurosurgeryFunction (biology)030304 developmental biologyCell Stem Cell
researchProduct

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

2019

Alessio Cortellini,1,2 Katia Cannita,1 Alessandro Parisi,1,2 Paola Lanfiuti Baldi,1 Olga Venditti,1 Carla D’Orazio,1,2 Antonella Dal Mas,3 Giuseppe Calvisi,3 Aldo V Giordano,4 Vincenzo Vicentini,5 Roberto Vicentini,5 Lara Felicioni,6 Antonio Marchetti,7 Fiamma Buttitta,6 Antonio Russo,8 Corrado Ficorella1,2 1Medical Oncology, St Salvatore Hospital, University of L’Aquila, L’Aquila, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 3Department of Pathology, St Salvatore Hospital L’Aquila, L’Aquila, Italy; 4Diagnostic and Interventional Radiology, St Salvatore Hos…

5-fluorouracil infusion; Bevacizumab; Clinical practice; Intensive chemotherapy regimen; Metastatic colorectal cancerintensive chemotherapy regimenmetastatic colorectal cancer intensive chemotherapy regimen bevacizumab clinical practice 5-fluorouracil infusionmetastatic colorectal cancer5-fluorouracil infusionbevacizumabOncoTargets and TherapyOriginal Researchclinical practiceOncoTargets and therapy
researchProduct

Incident colorectal cancer in Lynch syndrome is usually not preceded by compromised quality of colonoscopy

2019

AbstractBackground: Lifetime incidence of colorectal cancer (CRC) especially in carriers of MLH1 and MSH2 pathogenic germline variants in mismatch repair genes is high despite ongoing colonoscopy s...

AdenomaAdultMaleOncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHereditary non-polyposis colorectal cancerCOLONOSCOPYColorectal cancersurveillance colonoscopyeducationColonoscopycolorectal cancerMLH1Germline03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistriesneoplasmsFinlandAgedNeoplasm StagingRetrospective Studiesmedicine.diagnostic_testbusiness.industryIncidenceIncidence (epidemiology)LYNCH SYNDROMEGastroenterologynutritional and metabolic diseasesMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposisdigestive system diseasesLynch syndrome3. Good healthMSH2Population Surveillance030220 oncology & carcinogenesis3121 General medicine internal medicine and other clinical medicineFemale030211 gastroenterology & hepatologyDNA mismatch repairColorectal Neoplasmsbusiness
researchProduct

Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

2020

ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We com…

AdenomaMaleColorectal cancercolorectal cancerTarget populationcolorectal cancer screeningNOScreening programmeSingle indicatormedicineHumansMass ScreeningNational levelEarly Detection of CancerAgedPotential impactbusiness.industryIncidenceIncidence (epidemiology)GastroenterologyColonoscopycolorectal cancer; colorectal cancer screening; Adenoma; Aged; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Incidence; Italy; Male; Mass Screening; Middle Aged; Occult Blood; Patient Compliance; Program EvaluationMiddle Agedmedicine.diseaseItalyColorectal cancer screeningOccult BloodPatient ComplianceFemaleColorectal NeoplasmsbusinessProgram EvaluationDemographyGut
researchProduct

Havep53 gene mutations and protein expression a different biological significance in colorectal cancer?

2002

p53 alterations are considered the most common genetic events in many types of neoplasms, including colorectal carcinoma (CRC). These alterations include mutations of the gene and/or overexpression of the protein. The aim of our study was to assess whether in 160 patients undergoing resective surgery for primary operable CRC there was an association between p53 mutations and protein over-expression and between these and other biological variables, such as cell DNA content (DNA-ploidy) and S-phase fraction (SPF), and the traditional clinicopathological variables. p53 mutations, identified by PCR-SSCP-sequencing analysis, were found in 68/160 patients (43%) and positive staining for p53 prote…

AdultAged 80 and overMaleBase SequenceDNA Mutational AnalysisP53 colorectal cancerDNAMiddle AgedGenes p53ImmunohistochemistryProtein Structure TertiaryGene Expression Regulation NeoplasticMutationHumansFemaleGenetic TestingProspective StudiesIntestinal MucosaTumor Suppressor Protein p53Colorectal NeoplasmsAged
researchProduct

Upregulation of the netrin receptor (DCC) gene during activation of b lymphocytes and modulation by interleukins.

2001

The DCC (deleted in colon cancer) gene has a brain restricted high expression pattern. It encodes a transmembrane protein of the immunoglobulin superfamily identified as the netrin-1 receptor. It might be a member of the so called "brain-lymphoid" molecules, which control key cell surface events. To test this hypothesis we have assessed the DCC mRNA level in human normal and malignant myeloid and lymphoid cells. A high mRNA content has been observed only in mature B cells at the secreting or presecreting stage. Expression of DCC was also assessed in the anti-CD40 model of immunopoiesis. Activation of purified tonsillar B cells by anti-CD 40 antibody strongly increased the DCC mRNA level and…

AdultDeleted in Colorectal CancerTranscription GeneticT-LymphocytesPalatine TonsilBiophysicsReceptors Cell SurfaceBiologyLymphocyte ActivationBiochemistryCell LineNetrin Receptor DCCDownregulation and upregulationNetrinmedicineTumor Cells CulturedHumansRNA MessengerReceptorMolecular BiologyB cellB-LymphocytesReverse Transcriptase Polymerase Chain ReactionInterleukinsTumor Suppressor ProteinsfungiBrainCell BiologyDCC ReceptorMolecular biologyInterleukin-10Up-Regulationmedicine.anatomical_structureGenes DCCCell cultureImmunoglobulin superfamilyInterleukin-2Netrin ReceptorsCell Adhesion MoleculesImmunologic MemoryMuromonab-CD3Biochemical and biophysical research communications
researchProduct

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct